9.1 Manufacturers (Rx & OTC) & Virtual Manufacturers

The manufacturer sits at the very top of the pharmaceutical supply chain. It is the entity that holds the FDA approval for a drug and produces (or arranges production of) that drug. Everything downstream — wholesalers, repackagers, 3PLs, pharmacies — traces product back to a manufacturer. For the PTCB Supply Chain exam, you must know how Rx and OTC manufacturers reach market, what FDA registration they carry, and what DSCSA places on them.

How Drugs Reach Market: Rx vs OTC

Prescription (Rx) and over-the-counter (OTC) drugs take different regulatory pathways to market, and that difference shapes what the manufacturer must do.

Prescription Drugs — NDA, ANDA, and BLA

A new Rx drug reaches market through one of three FDA approval pathways:

• New Drug Application (NDA) — used for a new molecular entity or a major change to an existing product. The NDA is the most demanding pathway, requiring full clinical evidence of safety and efficacy. The manufacturer that holds an approved NDA is the reference listed drug (RLD) holder.
• Abbreviated New Drug Application (ANDA) — used for a generic drug. The ANDA applicant must demonstrate bioequivalence to the RLD but does not repeat the clinical trials. An ANDA holder is a manufacturer of a generic drug.
• Biologics License Application (BLA) — used for biological products (e.g., monoclonal antibodies, vaccines, biosimilars). A biosimilar is approved under a BLA, not an NDA.

OTC Drugs — Monograph or NDA

An OTC drug generally reaches market in one of two ways:

• OTC Monograph — FDA publishes a final monograph specifying the active ingredient, dose, indications, and labeling. A manufacturer that follows the monograph can market the OTC drug without a separate NDA. The monograph essentially pre-approves the product class.
• NDA — some OTC drugs (e.g., those first approved as Rx and then switched to OTC) are marketed under an NDA rather than under a monograph.

The exam often tests the monograph pathway as the OTC-specific route distinct from the Rx NDA/ANDA/BLA routes.

FDA Registration and Drug Listing

Every facility that manufactures a drug for the U.S. market must register with FDA and submit a National Drug Code (NDC) listing for each drug. Registration is the mechanism that places the facility under FDA inspection for current Good Manufacturing Practice (cGMP). cGMP covers everything from facility design and sanitation to batch records, stability testing, and quality release — a batch that fails cGMP release cannot legally enter commerce.

Key points the exam rewards:

• FDA registration is required of manufacturers — it is not optional.
• NDC listing assigns the 10- or 11-digit NDC that downstream trading partners use to identify the product.
• cGMP compliance is enforced through FDA inspection; a Form 483 may be issued for observed violations.

DSCSA Obligations on Manufacturers

Under the Drug Supply Chain Security Act (DSCSA), a manufacturer of a covered prescription product is an authorized trading partner and carries specific obligations:

• Serialization — the manufacturer must affix a product identifier (National Drug Code, serial number, lot number, and expiration date) in both human-readable and machine-readable (2D Data Matrix) form to each package. Serialization is the foundation of package-level traceability.
• T3 transaction data — when the manufacturer sells or transfers ownership of a covered product to the next trading partner, it must pass Transaction Information (TI), Transaction History (TH), and Transaction Statement (TS). TI contains the product identifier, lot, expiration date, transaction date, and quantity; TH is the chain of ownership back to the manufacturer; TS is the attestation by the seller.
• Suspect and illegitimate product — the manufacturer must investigate and notify FDA and immediate trading partners if it determines product is suspect or illegitimate, and must quarantine and not distribute illegitimate product.
• Verification — the manufacturer must respond to verification requests (e.g., a downstream dispenser asking "is this package legitimate?") within a specified timeframe.

Note that OTC monograph drugs are generally outside DSCSA. The serialization and T3 obligations attach to covered prescription products, which is why a technician must not assume every drug in the building carries T3 paper.

Manufacturer Sales Channels

The normal flow is manufacturer → wholesale distributor → pharmacy/hospital. Manufacturers sell the large majority of volume to wholesalers, who aggregate and distribute. Two narrower channels also exist:

• Direct-to-pharmacy / direct-to-hospital — some manufacturers (especially of specialty, limited-distribution, or cold-chain biologics) ship directly to a pharmacy or health system, bypassing the wholesaler. This is common for limited-distribution drugs (LDDs) and some specialty products.
• Authorized distribution network — a manufacturer may designate certain wholesalers as authorized distributors of its products. Product sold through the authorized network is presumptively genuine; product appearing outside that network raises a diversion flag.

Regardless of channel, DSCSA obligations follow the product: a manufacturer that sells direct to a hospital must still pass T3 data to that hospital.

Virtual Manufacturers

A virtual manufacturer is an entity that owns the product and the FDA approval (the NDA, ANDA, or BLA is held in its name) but outsources the physical work: a contract manufacturer makes the drug, and a Third-Party Logistics provider (3PL) warehouses and ships it. The virtual manufacturer does not operate its own production line or its own warehouse.

Why this matters for the exam:

• A virtual manufacturer is still a manufacturer for regulatory purposes — it must register with FDA, it is an authorized trading partner under DSCSA, and it must serialize and pass T3.
• The fact that physical handling is contracted out does not move the virtual manufacturer into the "wholesaler" or "3PL" box. Ownership of the approval — not ownership of the building — defines the role.
• A common exam trap is to treat a virtual manufacturer as something less than a manufacturer because it has no factory. The correct view is the opposite: it carries the same manufacturer obligations, layered on top of contract oversight of its contract manufacturer and 3PL.

Summary Table — Manufacturer Types

The unifying rule: registration and DSCSA obligations attach to the entity that holds the approval and puts the product into commerce, whether or not it runs the factory. The pathway (NDA/ANDA/BLA/monograph) determines the approval burden; DSCSA determines the downstream traceability burden.